T CELL ACTIVATION AND FUNCTIONAL AVIDITY
T CELL ACTIVATION AND FUNCTIONAL AVIDITY
批准号:
7958426
负责人:
MARK K SLIFKA
金额:
$8.03万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-04 至 2010-04-30
关键词:
AcuteAddressAntigensAntiviral AgentsAvidityBiological AssayCD8B1 geneCellsCellular ImmunityComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantImmunologyInstitutionInvestigationKnowledgeMeasuresParasitic infectionPeptide/MHC ComplexPeptidesPopulationPrimatesProcessProductionReceptor SignalingResearchResearch PersonnelResourcesSignal TransductionSourceT-Cell ReceptorT-LymphocyteTransgenic MiceUnited States National Institutes of HealthVaccine DesignVirus Diseasesclinically relevantcytokineimprovedmicrobialresponsesuccessvaccination strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
CD8+ T cells are critical for the control and clearance of many microbial and parasitic infections, and are key to the success of many potential vaccination strategies. Despite the broad clinical relevance of T cell-mediated immunity and the intense investigation of this subject, the underlying mechanisms involved with eliciting effective T cell responses still remain to be fully determined. To begin to address this issue, we have analyzed antigen-specific T cells directly ex vivo using peptide/MHC-tetramers and functional assays that measure cytolytic activity and cytokine production. Following acute viral infection, we have found that T cell responsiveness (termed functional avidity) to peptide antigen increased significantly in both normal and T cell receptor (TcR) transgenic mice, even though TcR avidity remained virtually unaltered. Preliminary analysis of Lck expression and function indicates that pre-assembly of the TcR signal transduction machinery may serve as an important mechanism for decreasing the threshold of activation in antigen-specific CD8+ T cells. The focus of this proposal is to more thoroughly characterize the process of functional avidity maturation by dominant and subdominant CD8+ T cell populations during the course of acute viral infection, and to determine if increased antigen sensitivity is related to increased Lck expression, localization, and/or its state of activation. The results of these studies will be important for improving vaccine design as well as furthering our knowledge of antiviral T cell immunology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8267908
-
项目类别:
-
资助金额:$132.76万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8840142
-
项目类别:
-
资助金额:$151.33万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8651871
-
项目类别:
-
资助金额:$148.82万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8463114
-
项目类别:
-
资助金额:$158.91万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED
-
批准号:8357801
-
项目类别:
-
资助金额:$5.82万
-
财政年份:2011
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS
-
批准号:8357802
-
项目类别:
-
资助金额:$10.91万
-
财政年份:2011
-
负责人:MARK K SLIFKA
-
依托单位:
T CELL ACTIVATION AND FUNCTIONAL AVIDITY
-
批准号:8173191
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS
-
批准号:8173258
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED
-
批准号:8173291
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS
-
批准号:8173292
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
VACCINE-INDUCED CD8+ T CELL MEMORY
-
批准号:8173257
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
CYTOKINE-MEDIATED T CELL ACTIVATION
-
批准号:8173199
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
VACCINE-INDUCED CD8+ T CELL MEMORY
-
批准号:7958529
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS
-
批准号:7958530
-
项目类别:
-
资助金额:$6.04万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a new yellow fever vaccine for vulnerable populations
-
批准号:7676346
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:8238380
-
项目类别:
-
资助金额:$109.74万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:7644679
-
项目类别:
-
资助金额:$79.65万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:8054391
-
项目类别:
-
资助金额:$303.98万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
CYTOKINE-MEDIATED T CELL ACTIVATION
-
批准号:7958438
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:7797564
-
项目类别:
-
资助金额:$212.83万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
海外基金